The over-exaggerated chronic nephrotoxicity of calcineurin inhibitors

scientific article published on 07 April 2012

The over-exaggerated chronic nephrotoxicity of calcineurin inhibitors is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.AJU.2012.02.003
P8608Fatcat IDrelease_3barcrmywfahdbbdqdbjcalfmq
P932PMC publication ID4442887
P698PubMed publication ID26558021
P5875ResearchGate publication ID257737182

P2093author name stringAleksandra Kukla
Hassan N Ibrahim
Naim Issa
P2860cites workSpecificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapyQ84870337
Histological characteristics of calcineurin inhibitor toxicity--there is no such thing as specificity!Q84870341
Chronic renal failure after transplantation of a nonrenal organQ28204928
Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipientsQ36677625
Chronic kidney disease after nonrenal solid-organ transplantationQ37015132
Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim resultQ37097694
Renal biopsy in liver transplant recipientsQ37416844
Long-Term Renal Allograft Survival in the United States: A Critical ReappraisalQ39824383
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.Q42111937
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failureQ42171636
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study GroupQ42277471
Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.Q42620122
The variable pathology of kidney disease after liver transplantationQ43185129
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failureQ43918875
Predictors of renal function following lung or heart-lung transplantationQ44004857
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).Q44247085
The natural history of chronic allograft nephropathyQ44688416
Identifying specific causes of kidney allograft loss.Q45810388
Chronic kidney disease after heart transplantation.Q46147919
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trialQ46155747
The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipientsQ46233987
Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortalityQ46485592
Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus.Q46630981
A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 yearQ46636291
Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimusQ46645995
Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation.Q46702764
Reduced exposure to calcineurin inhibitors in renal transplantationQ46840533
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimusQ46936585
Reversal of lesions of diabetic nephropathy after pancreas transplantationQ47879758
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre studyQ57943257
Cyclosporine-associated chronic nephropathyQ70376376
Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantationQ70813564
Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity modelQ71463351
Sirolimus and cyclosporin for renal transplantationQ74236870
Chronic cyclosporine nephrotoxicityQ74623627
The side-effects of ciclosporine-A and tacrolimusQ77059728
Risks and outcomes of acute kidney injury requiring dialysis after cardiac transplantationQ79293655
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR StudyQ79576315
Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantationQ79858857
Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantationQ80563022
Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levelsQ81964906
The histology of solitary renal allografts at 1 and 5 years after transplantationQ82379183
Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawalQ82427002
A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysisQ82996497
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trialQ83059944
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)Q84102539
P433issue2
P304page(s)169-174
P577publication date2012-04-07
P1433published inArab Journal of Urology Arab Association of UrologyQ26842822
P1476titleThe over-exaggerated chronic nephrotoxicity of calcineurin inhibitors
P478volume10

Reverse relations

Q53702610Calcineurin inhibitors and nephrotoxicity in children.cites workP2860

Search more.